UNSPSC 51182435: Teriparatide

This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10T9CSU89I, chemically known as l-phenylalanine, l-seryl-l-valyl-l-seryl-l-alpha-glutamyl-l-isoleucyl-l-glutaminyl-l-leucyl-l-methionyl-l-histidyl-l-asparaginyl-l-leucylglycyl-l-lysyl-l-histidyl-l-leucyl-l-asparaginyl-l-seryl-l-methionyl-l-alpha-glutamyl-l-arginyl-l-valyl-l-alpha-glutamyl-l-tryptophyl-l-leucyl-l-arginyl-l-lysyl-l-lysyl-l-leucyl-l-glutaminyl-l-alpha-aspartyl-l-valyl-l-histidyl-l-asparaginyl- but generally known as teriparatide, which bears US NIH Compound Identifier 16129682.

UNSPSC 51182435 Teriparatide is a Commodity code covering injectable pharmaceutical products for osteoporosis treatment. State and local governments procure this medication through cooperative purchasing alliances and multistate pharmaceutical agreements to supply hospital systems, correctional facilities, public health clinics, and other government-operated healthcare entities. The work involves establishing supply contracts with manufacturers or authorized distributors who maintain cGMP certification, Drug Supply Chain Security Act compliance, and established relationships with licensed pharmaceutical wholesalers. Issuing bodies include state departments of administration, multistate cooperative purchasing organizations, and regional health authorities that aggregate demand across multiple member jurisdictions to negotiate volume pricing and ensure reliable access to brand-name and generic formulations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with participation from Oregon and other member states. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates submission of detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations. Proposals were due March 26, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security liability of $2,000,000, and professional liability of $2,000,000, with contract terms of two years for new responders and optional extensions at MMCAP's discretion through June 30, 2028 for incumbents.